

	Enrolment at First-Line Treatment				Enrolment at Second-Line Treatment			
	Total N=620	BR N=348	FCR N=137	B N=33	Total N=186	BR N=107	FCR N=21	B N=20
Age at primary diagnosis [n] ^a	616	346	136	33	185	106	21	20
Mean ± StD [yrs]	66.2 ± 10.6	66.8 ± 10.2	60.0 ± 10.0	73.6 ± 5.4	65.1 ± 9.5	65.2 ± 9.0	58.9 ± 9.3	66.9 ± 8.7
Median [yrs]	67.8	68.0	61.3	74.0	66.3	66.6	60.1	67.2
Range [yrs]	20.9 - 91.7	31.1 - 91.7	20.9 - 75.5	64.7 - 85.5	34.6 - 87.2	39.4 - 87.2	34.6 - 71.9	48.0 - 86.6
Age at start of therapy [n] ^b	620	348	137	33	186	107	21	20
Mean ± StD [yrs]	69.6 ± 10.2	70.2 ± 9.5	63.0 ± 9.5	77.8 ± 4.5	71.6 ± 9.2	72.0 ± 8.0	64.2 ± 10.8	74.1 ± 8.6
Median [yrs]	70.8	71.2	64.6	77.6	72.5	72.4	67.0	73.0
Range [yrs]	21.3 - 92.1	31.7 - 92.1	21.3 - 81.9	69.9 - 86.3	38.4 - 93.7	46.2 - 88.8	38.4 - 81.0	55.4 - 93.7
< 70 yrs [%]	45.2	42.5	73.7	3.0	36.0	33.6	71.4	25.0
Male [%]	64.2	65.2	71.5	54.5	57.0	57.0	57.1	50.0
BMI [n] ^a	604	341	135	33	183	105	20	20
Mean ± StD [kg/m ²]	26.1 ± 4.1	26.1 ± 3.9	26.2 ± 3.5	26.5 ± 5.4	26.3 ± 4.8	26.6 ± 5.1	26.3 ± 6.3	24.6 ± 2.2
underweight < 18.5 [%]	1.0	0.6	-	3.0	2.2	2.9	5.0	-
obese >30 [%]	15.4	14.7	17.0	18	16.4	18.1	20.0	-
Body Surface Area [n] ^a	604	341	135	33.0	183	105	20	20
Mean ± StD [m ²]	1.9 ± 0.2	1.9 ± 0.2	1.9 ± 0.2	1.9 ± 0.2	1.8 ± 0.2	1.9 ± 0.2	1.9 ± 0.2	1.8 ± 0.2
Time between primary diagnosis and start of initial therapy [n]	614	345	136	32	178	103	20	19
Mean ± StD [yrs]	3.5 ± 4.2	3.5 ± 4.2	3.0 ± 3.8	4.3 ± 4.3	3.1 ± 3.5	3.2 ± 3.8	2.5 ± 2.8	3.8 ± 3.0
Median [yrs]	2.1	2.1	1.7	3.5	2.0	2.0	1.8	4.2
Range [yrs]	0.0 - 23.6	0.0 - 23.3	0.0 - 23.6	0.0 - 15.2	0.0 - 29.8	0.0 - 29.8	0.0 - 10.5	0.0 - 8.7

	Enrolment at First-Line Treatment								Enrolment at Second-Line Treatment							
	Total N=620		BR N=348		FCR N=137		B N=33		Total N=186		BR N=107		FCR N=21		B N=20	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
ECOG Performance ^a	571		320		131		28		165		94		18		18	
0	226	39.6	131	40.9	57	43.5	8	28.6	51	30.9	33	35.1	9	50.0	6	33.3
1	292	51.1	162	50.6	67	51.1	15	53.6	93	56.4	54	57.4	9	50.0	10	55.6
2	48	8.4	26	8.1	7	5.3	2	7.1	21	12.7	7	7.4	-	-	2	11.1
3	5	0.9	1	0.3	-	-	3	10.7	-	-	-	-	-	-	-	-
4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tumour Stage ^a	608		340		135		32		177		101		21		18	
Binet A	123	20.2	66	19.4	27	20.0	8	25.0	35	19.8	18	17.8	4	19.0	3	16.7
Binet B	218	35.9	123	36.2	61	45.2	7	21.9	63	35.6	39	38.6	11	52.4	3	16.7
Binet C	267	43.9	151	44.4	47	34.8	17	53.1	79	44.6	44	43.6	6	28.6	12	66.7
Splenomegaly ^a	595		337		130		32		167		94		19		19	
Presence	374	62.9	216	64.1	80	61.5	24	75.0	91	54.5	55	58.5	8	42.1	10	52.6
Hepatomegaly ^a	587		331		132		31		164		93		19		19	
Presence	75	12.8	47	14.2	15	11.4	4	12.9	23	14.0	16	17.2	1	5.3	1	5.3
Coombs-Test ^a	153		83		33		8		33		18		3		3	
positive	34	22.2	18	21.7	4	12.1	4	50.0	10	30.3	4	22.2	1	33.3	2	66.7
Leukocytes ^a	607		343		133		30		182		105		21		19	
(>15.000/μL)	461	75.9	259	75.5	108	81.2	20	66.7	119	65.4	67	63.8	15	71.4	13	68.4
Lymphocytes ^a	482		280		96		24		149		89		18		16	
(>5.000/μL)	381	79.0	221	78.9	80	83.3	17	70.8	113	75.8	64	71.9	14	77.8	13	81.3
Thrombocytes ^a	608		343		133		31		183		104		21		20	
(<100.000/μL)	156	25.7	90	26.2	30	22.6	8	25.8	52	28.4	28	26.9	3	14.3	8	40.0

	Enrolment at First-Line Treatment								Enrolment at Second-Line Treatment							
	Total N=620		BR N=348		FCR N=137		B N=33		Total N=186		BR N=107		FCR N=21		B N=20	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Haemoglobin ^a	610		345		133		31		184		105		21		20	
(<10g/dL)	147	24.1	81	23.5	24	18.0	10	32.3	45	24.5	21	20.0	3	14.3	9	45.0
LDH ^a	591		333		133		32		182		104		21		20	
elevated	245	41.5	142	42.6	43	32.3	13	40.6	79	43.4	45	43.3	10	47.6	9	45.0
Comorbidities ^a	620		348		137		33		185		106		21		20	
Presence	429	69.2	237	68.1	85	62.0	27	81.8	135	73.0	80	75.5	10	47.6	16	80.0
Charlson Comorbidity Index (CCI) Mean ± StD [0-34]	0.8 ± 1.3		0.7 ± 1.2		0.6 ± 1.0		1.5 ± 1.7		0.9 ± 1.3		0.9 ± 1.2		0.5 ± 0.9		1.3 ± 1.6	
CCI 0	377		215		94		10		101		58		15		9	
CCI 1	118		67		22		11		35		20		3		3	
CCI 2	77		41		14		6		29		18		2		5	
CCI 3	24		13		2		3		8		4		1		1	
CCI 4	9		4		3		-		9		5		-		1	
CCI 5	6		3		2		1		1		-		-		-	
CCI 6	5		2		-		1		2		1		-		1	
CCI 7	3		2		-		1		-		-		-		-	
CCI 8	1		1		-		-		-		-		-		-	
Cardiovascular disorders	274	44.2	147	42.2	50	36.5	19	57.6	76	41.1	44	41.5	4	19.0	10	50.0
Diabetes	99	16.0	53	15.2	22	16.1	10	30.3	29	15.7	12	11.3	3	14.3	6	30.0
Renal disorders	31	5.0	18	5.2	3	2.2	3	9.1	22	11.9	11	10.4	-	-	4	20.0
Other Tumour	57	9.2	31	8.9	9	6.6	4	12.1	21	11.4	13	12.3	3	14.3	3	15.0

	Enrolment at First-Line Treatment								Enrolment at Second-Line Treatment							
	Total N=620		BR N=348		FCR N=137		B N=33		Total N=186		BR N=107		FCR N=21		B N=20	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
B-Symptoms ^a	606		341		132		33		184		106		20		20	
Presence of B-Symptoms	176	29.0	98	28.7	38	28.8	10	30.3	48	26.1	32	30.2	4	20.0	3	15.0
Fever	15	2.5	11	3.2	1	0.8	-	-	4	2.2	3	2.8	1	5.0	-	-
Night sweats	139	22.9	73	21.4	34	25.8	10	30.3	38	20.7	25	23.6	4	20.0	3	15.0
Weight loss	62	10.2	37	10.9	10	7.6	6	18.2	17	9.2	10	9.4	-	-	1	5.0
Enlarged lymph node regions ^a	386		219		89		18		100		60		14		8	
0	52	13.5	32	14.6	4	4.5	3	16.7	11	11.0	6	10.0	1	7.1	1	12.5
1 or 2	78	20.2	38	17.4	17	19.1	5	27.8	22	22.0	12	20.0	1	7.1	5	62.5
≥3	256	66.3	149	68.0	68	76.4	10	55.6	67	67.0	42	70.0	12	85.7	2	25.0
Bulky disease (lymphadenopathy) ^a	558		314		120		31		163		93		20		19	
Presence	67	12.0	37	11.8	18	15.0	5	16.1	27	16.6	17	18.3	6	30.0	1	5.3

^a Parameter available for all patients at the time of their enrolment.

^b Age at the time of enrolment into registry.

Abbreviations:

B: bendamustine ± prednisone | BR: bendamustine + rituximab ± prednisone | FCR: fludarabine+ cyclophosphamide + rituximab ± prednisone

BMI: body mass index; CCI: Charlson Comorbidity Index; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; StD: standard deviation; yrs: years